Search research articles
Contact Us
Filters
Showing results (151-160 of 283) with videos related to
Page
of 29
Sort By:
Leukemia Research
|
August 10, 2016
Phase I study of azacitidine following donor lymphocyte infusion for relapsed acute myeloid leukemia post allogeneic stem cell transplantation
Armin Ghobadi, Jaebok Choi, Mark A Fiala, et al.
Leukemia & Lymphoma
|
November 1, 2018
Health related quality of life for multiple myeloma patients according to treatment strategy after autologous stem cell transplant: a cross-sectional study using EORTC, EQ-5D and MY-20 scales
Jason Tay, Ravi Vij, Maxim Norkin, et al.
Leukemia
|
November 21, 2021
Treatment outcomes of triple class refractory multiple myeloma: a benchmark for new therapies
Susan Bal, Ehsan Malek, Ankit Kansagra, et al.
Leukemia
|
September 16, 2022
Ixazomib, lenalidomide and dexamethasone consolidation with randomized ixazomib or lenalidomide maintenance after autologous transplant in newly diagnosed multiple myeloma
Michael Slade, Thomas G Martin, Nitya Nathwani, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society
|
December 3, 2017
Enhancing proteasome-inhibitory activity and specificity of bortezomib by CD38 targeted nanoparticles in multiple myeloma
Pilar de la Puente, Micah J Luderer, Cinzia Federico, et al.
Haematologica
|
October 17, 2024
Belantamab mafodotin monotherapy for relapsed or refractory multiple myeloma: a real-world observational study in the United States
Malin Hultcrantz, David Kleinman, Ravi Vij, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
April 24, 2020
Long-Term Follow-up of CALGB (Alliance) 100001: Autologous Followed by Nonmyeloablative Allogeneic Transplant for Multiple Myeloma
Sarah A Holstein, Vera J Suman, Kouros Owzar, et al.
Cancer Chemotherapy and Pharmacology
|
August 29, 2014
Effect of age on the pharmacokinetics of busulfan in patients undergoing hematopoietic cell transplantation; an alliance study (CALGB 10503, 19808, and 100103)
Jan H Beumer, Kouros Owzar, Lionel D Lewis, et al.
The Lancet. Haematology
|
December 22, 2015
Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b-2 dose-escalation study
Paul G Richardson, Sundar Jagannath, Philippe Moreau, et al.
American Journal of Hematology
|
October 7, 2009
Salvage therapy for acute myeloid leukemia with fludarabine, cytarabine, and idarubicin with or without gemtuzumab ozogamicin and with concurrent or sequential G-CSF
Mike G Martin, Kristan M Augustin, Geoffrey L Uy, et al.
Page
of 29
Search research articles
Search
Showing results (151-160 of 283) with videos related to
Sort By:
Page
of 29
Leukemia Research
|
August 10, 2016
Phase I study of azacitidine following donor lymphocyte infusion for relapsed acute myeloid leukemia post allogeneic stem cell transplantation
Armin Ghobadi, Jaebok Choi, Mark A Fiala, et al.
Leukemia & Lymphoma
|
November 1, 2018
Health related quality of life for multiple myeloma patients according to treatment strategy after autologous stem cell transplant: a cross-sectional study using EORTC, EQ-5D and MY-20 scales
Jason Tay, Ravi Vij, Maxim Norkin, et al.
Leukemia
|
November 21, 2021
Treatment outcomes of triple class refractory multiple myeloma: a benchmark for new therapies
Susan Bal, Ehsan Malek, Ankit Kansagra, et al.
Leukemia
|
September 16, 2022
Ixazomib, lenalidomide and dexamethasone consolidation with randomized ixazomib or lenalidomide maintenance after autologous transplant in newly diagnosed multiple myeloma
Michael Slade, Thomas G Martin, Nitya Nathwani, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society
|
December 3, 2017
Enhancing proteasome-inhibitory activity and specificity of bortezomib by CD38 targeted nanoparticles in multiple myeloma
Pilar de la Puente, Micah J Luderer, Cinzia Federico, et al.
Haematologica
|
October 17, 2024
Belantamab mafodotin monotherapy for relapsed or refractory multiple myeloma: a real-world observational study in the United States
Malin Hultcrantz, David Kleinman, Ravi Vij, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
April 24, 2020
Long-Term Follow-up of CALGB (Alliance) 100001: Autologous Followed by Nonmyeloablative Allogeneic Transplant for Multiple Myeloma
Sarah A Holstein, Vera J Suman, Kouros Owzar, et al.
Cancer Chemotherapy and Pharmacology
|
August 29, 2014
Effect of age on the pharmacokinetics of busulfan in patients undergoing hematopoietic cell transplantation; an alliance study (CALGB 10503, 19808, and 100103)
Jan H Beumer, Kouros Owzar, Lionel D Lewis, et al.
The Lancet. Haematology
|
December 22, 2015
Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b-2 dose-escalation study
Paul G Richardson, Sundar Jagannath, Philippe Moreau, et al.
American Journal of Hematology
|
October 7, 2009
Salvage therapy for acute myeloid leukemia with fludarabine, cytarabine, and idarubicin with or without gemtuzumab ozogamicin and with concurrent or sequential G-CSF
Mike G Martin, Kristan M Augustin, Geoffrey L Uy, et al.
Page
of 29